Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals | Hong Kong | Healthcare | Pharmaceuticals | HK$465.52B | 55.3x | 1.66 | HK$74 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.1% Upside | Upgrade to Pro+ | |
| WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$310.98B | 20x | 0.6 | HK$103.70 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.6% Upside | Upgrade to Pro+ | |
| BeOne Medicines HK | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$265.61B | -199.9x | -2.93 | HK$187.60 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.8% Upside | Upgrade to Pro+ | |
| Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$217.09B | 39.9x | 6.95 | HK$35.86 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
| Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$154.56B | 122.5x | 0.65 | HK$90.20 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.9% Upside | Upgrade to Pro+ | |
| WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$147.15B | 37.9x | 0.5 | HK$35.62 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0% Downside | Upgrade to Pro+ | |
| Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$127.28B | 30.2x | -8.37 | HK$7.12 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.1% Upside | Upgrade to Pro+ | |
| Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$108.97B | -133.7x | 10.67 | HK$118.30 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$105.21B | -150.3x | 0.48 | HK$451.20 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | |
| WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$92.28B | 66.9x | 0.59 | HK$72.70 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.4% Downside | Upgrade to Pro+ | |
| CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$87.92B | 21x | -0.63 | HK$7.69 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.9% Upside | Upgrade to Pro+ | |
| Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$79.33B | 23.6x | 0.4 | HK$23.68 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.5% Upside | Upgrade to Pro+ | |
| 3SBio | Hong Kong | Healthcare | Pharmaceuticals | HK$75.98B | 30.3x | 0.7 | HK$31.78 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22% Upside | Upgrade to Pro+ | |
| TransThera Sciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$75.13B | -282x | -15.36 | HK$189.30 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$65.37B | 11.7x | 0.2 | HK$11.82 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.3% Upside | Upgrade to Pro+ | |
| Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$61.44B | 39x | -1.95 | HK$25.62 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.1% Upside | Upgrade to Pro+ | |
| Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$60.23B | 7.8x | -0.57 | HK$19.30 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.2% Upside | Upgrade to Pro+ | |
| Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$56.51B | -47.2x | -1.54 | HK$92.85 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -18.7% Downside | Upgrade to Pro+ | |
| Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$53.97B | 84.5x | -2.23 | HK$46.66 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.9% Upside | Upgrade to Pro+ | |
| XtalPi Holdings | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$48.88B | -202.4x | -2.31 | HK$11.41 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -7.1% Downside | Upgrade to Pro+ | |
| Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$45.11B | 14.6x | -1.08 | HK$19.07 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
| Shanghai Junshi Biosciences | Hong Kong | Healthcare | Pharmaceuticals | HK$40.61B | -25.4x | -0.83 | HK$26.70 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.3% Upside | Upgrade to Pro+ | |
| Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$38.17B | 34.6x | -32.32 | HK$85.65 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.9% Upside | Upgrade to Pro+ | |
| Henlius Biotech | Hong Kong | Healthcare | Pharmaceuticals | HK$37.96B | 47.8x | 2.17 | HK$69.10 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42% Upside | Upgrade to Pro+ | |
| Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$37.24B | -285.8x | 0.56 | HK$17.04 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.8% Upside | Upgrade to Pro+ | |
| Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$34.44B | 32.2x | 0.18 | HK$13.27 | 7.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.2% Upside | Upgrade to Pro+ | |
| Xuanzhu Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$34.37B | -46.7x | HK$66.35 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$33.47B | 18.5x | 0.9 | HK$13.85 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.8% Upside | Upgrade to Pro+ | |
| Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$33.06B | 15.4x | 1.57 | HK$31.74 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19% Upside | Upgrade to Pro+ | |
| China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$31.41B | 10.2x | -0.4 | HK$5 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40% Upside | Upgrade to Pro+ | |
| Ping An Healthcare Tech | Hong Kong | Healthcare | Healthcare Providers & Services | HK$31.12B | 128.8x | 0.28 | HK$14.42 | 4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
| China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$30.78B | 14.7x | -1.01 | HK$8.79 | 6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.5% Upside | Upgrade to Pro+ | |
| Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$28.77B | 70.7x | 0.69 | HK$20.74 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.9% Upside | Upgrade to Pro+ | |
| Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$28.48B | -117.2x | -2.28 | HK$14.62 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.4% Upside | Upgrade to Pro+ | |
| Shanghai MicroPort MedBot | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$28.28B | -52.3x | -1.41 | HK$27.12 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.5% Upside | Upgrade to Pro+ | |
| Duality Biotherapeutics | Hong Kong | Healthcare | Pharmaceuticals | HK$27.64B | -2.4x | HK$315.60 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37% Upside | Upgrade to Pro+ | ||
| Sunshine Lake Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$26.41B | 20.1x | -0.66 | HK$48 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -69.1% Downside | Upgrade to Pro+ | |
| United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$25.49B | 7x | 1.39 | HK$12.92 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.2% Upside | Upgrade to Pro+ | |
| Shandong Weigao Medical Polymer | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$25.11B | 11.8x | 3.24 | HK$5.52 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.6% Upside | Upgrade to Pro+ | |
| Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$24.47B | -17.6x | 0.1 | HK$67.90 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40% Upside | Upgrade to Pro+ | |
| Shanghai Conant Optics | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$23.18B | 37.8x | 1.59 | HK$48.30 | 7.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.2% Upside | Upgrade to Pro+ | |
| MicroPort Scientific | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$22.94B | -16.5x | -0.3 | HK$11.99 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.2% Upside | Upgrade to Pro+ | |
| Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$22.60B | -17.6x | -0.39 | HK$21.02 | 4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$19.26B | 5.7x | 0 | HK$23.76 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.8% Upside | Upgrade to Pro+ | |
| MiRXES Holding | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$18.57B | -16.5x | HK$67.70 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.5% Upside | Upgrade to Pro+ | ||
| Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$18.05B | 43.2x | 0.15 | HK$5.54 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -20% Downside | Upgrade to Pro+ | |
| Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$17.75B | -66x | -0.96 | HK$64.20 | 6.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.9% Upside | Upgrade to Pro+ | |
| Pegbio | Hong Kong | Healthcare | Pharmaceuticals | HK$16.78B | -79.4x | HK$60.50 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| Cansino Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$16.03B | -70.2x | -1.29 | HK$47.20 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.1% Upside | Upgrade to Pro+ | |
| Ab B Bio Tech | Hong Kong | Healthcare | Pharmaceuticals | HK$15.67B | HK$39.84 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |